26 Velásquez y col.
Investigación Clínica 64(1): 2023
rer R, Michelena E, Rodríguez L, Silva J,
Moronta A, Espinoza G, Quintero L. Perfil
dopaminérgico del compuesto 2-aminoin-
dano-N-aralquil sustituido. Arch Venezol Te-
rap Farmacol 2004; 23(2): 136-142.
15. Andujar S, Garibotto F, Migliore B, Angel
J, Charris J, Enriz R. Molecular recogni-
tion and binding mechanism of N-aralkyl
substituted 2-aminoindans to the dopami-
ne D2 receptor. A theoretical study. J Ar-
gent Chem Soc 2006; 94: 1-11.
16. Angel J. Una compilación en el diseño y
evaluación farmacológica preliminar de
nuevos compuestos con actividad dopami-
nérgica central. Invest Clin 2008; 49(1):
71-73.
17. Andujar S, Migliore B, Charris J, Israel
A, Suárez H, López S, Garrido M, Cabre-
ra E, Visbal G, Rosales C, Suvire F, Enriz
R, Angel J. Synthesis, dopaminergic profile
and molecular dynamics calculations of N-
Aralkyl substituted 2-aminoindans. Bioorg
Med Chem 2008; 16(6): 3233-3244. https://
doi.org/10.1016/j.bmc.2007.12.027
18. Ferrer R, Urdaneta N, Porta N, Rodríguez
L, Rosales C, Espinoza G, Angel L, Balza
K, Perdomo L, Faría A, Dabian A, Zapata
M, Linero A, Acurero G, Israel A, Garrido
M, Suárez H, Migliore B, López S, Charris
J, Ramírez M, Angel J. Novedosos agen-
tes dopaminérgicos centrales derivados del
2-aminoindano-4,7disustituido atípico. Sín-
tesis y perfil farmacológico central. Invest
Clin 2015; 56(2): 137-154.
19. Perdomo L, Balza K, Acurero G, Angel
L, Dabian A, Faría A, Linero A, Zapata
M, Vera M, Migliore, Suárez H, Israel A,
Charris J, López S, Ramírez M, Angel J.
Design, synthesis and preliminary pharma-
cologic evaluation of 2-aminoindane-quino-
line analogues as dopaminergic agents. Der
Pharma Chem 2015; 7(5): 130-135.
20. Montero L, Velasquez M, Caldera J, Vera
M, Blanco C, Angel L, Migliore B, Charris
J, Israel A, López S, Izquierdo R, Ortega
J, Ramírez M, Angel J. Síntesis y evalua-
ción farmacológica de los novedosos agen-
tes dopaminérgicos centrales análogos del
N-dicloroaralquil-2-aminoindano. Rev Fac
Farm 2018; 81(1-2): 41-50.
21. Castall B, Marsden CD, Naylor RJ, Pycock
CJ. Stereotyped behavior patterns and hy-
peractivity induced by amphetamine and
apomorphine after discrete 6-hydroxydopa-
mine lesions of extrapyramidal and meso-
limbic nuclei. Brain Res 1977; 123(1): 89-
111. https://doi.org/10.1016/0006-8993
(77)90645-X.
22. Snedecord G, Cochnar W. Statistical
Methods. 7th Ed USA: Iowa State University
Press Ames; 1982.
23. Costall B, Naylor RJ, Cannon JG, Lee
TJ. Differentiation of the dopamine me-
chanisms mediating stereotyped behavior
and hyperactivity in the nucleus accum-
bens and caudate-putamen. J Pharm Phar-
macol 1977; 29(1): 337-342. https://doi.
org/10.1111/j.2042-7158.1977.tb11331.x
24. Creese L, Iversen SD. The pharmacolo-
gical and anatomical substrates of the
amphetamine response in the rat. Brain
Res 1975; 83(3): 419-436. https://doi.
org/10.1016/0006-8993(75)90834-3
25. Chartoff EH, Marck BT, Matsumoto AM,
Dorsa DM, Palmiter RD. Induction of ste-
reotypy in dopamine-deficient mice requi-
res striatal D1 receptor activation. Proc Natl
Acad Sci USA 2001; 98(18): 10451-10456.
https://doi.org/10.1073/pnas.181356498
26. Israel A, Torres M, Cierco M, Barbella
Y. Further evidence for a dopaminergic
involvement in the renal action of cen-
trally administered atrial natriuretic pep-
tide in rats. Brain Res Bull 1991; 27(5):
739-742. https://doi.org/10.1016/0361-
9230(91)90056-P
27. Orfila L, Angel J, Torres M, Barbella Y, Israel
A. Evidence for a dopaminergic involvement
in the renal action of centrally administered
JA116a, a novel compound with possible do-
paminergic activity in rats. J Pharm Phar-
macol 1994; 46(5): 397-399. https://doi.
org/10.1111/j.2042-7158.1994.tb03825.x
28. Seeger TF, Seymour PA, Schmidt AW, Zorn
SH, Schulz DW, Lebel LA, McLean S, Gua-
nowsky V, Howard HR, Lowe JA. Ziprasido-
ne (CP-88,059): A new antipsychotic with
combined dopamine and serotonin recep-
tor antagonist activity. J Pharmacol Exp
Ther 1995; 275(1): 101-113.
29. Murphy S, Owen R, Tyrer P. Comparati-
ve assessment of efficacy and withdrawal
symptoms after 6 and 12 weeks treatment
with diazepam or buspirone. Br J Psychia-